A Phase II Randomized Study to Determine the Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Phase II Randomized Study to Determine the Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Cetuximab
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms PembroRad
  • Most Recent Events

    • 26 Oct 2017 Planned End Date changed from 1 Aug 2018 to 1 Jun 2020.
    • 26 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2019.
    • 26 Oct 2017 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top